Lazard Asset Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-96,420
| Closed | -$4.66M | – | 2485 |
|
|
2025
Q1 | $4.66M | Buy |
+96,420
| New | +$4.66M | 0.01% | 707 |
|
|
2024
Q4 | – | Sell |
-2,697
| Closed | -$121K | – | 2484 |
|
|
2024
Q3 | $121K | Sell |
2,697
-3,374
| -56% | -$151K | ﹤0.01% | 1740 |
|
|
2024
Q2 | $210K | Buy |
6,071
+3,656
| +151% | +$126K | ﹤0.01% | 1542 |
|
|
2024
Q1 | $69K | Buy |
+2,415
| New | +$69K | ﹤0.01% | 1651 |
|
|
2023
Q1 | – | Sell |
-6,404
| Closed | -$69K | – | 2502 |
|
|
2022
Q4 | $69K | Hold |
6,404
| – | – | ﹤0.01% | 1671 |
|
|
2022
Q3 | $53K | Hold |
6,404
| – | – | ﹤0.01% | 1775 |
|
|
2022
Q2 | $50K | Buy |
+6,404
| New | +$50K | ﹤0.01% | 1814 |
|
|
2021
Q1 | – | Sell |
-2,607
| Closed | -$52K | – | 1986 |
|
|
2020
Q4 | $52K | Buy |
+2,607
| New | +$52K | ﹤0.01% | 1375 |
|